Leveraging epitranscriptomics for cardiovascular disease theranostics.

This article discusses the need for new approaches in managing cardiovascular diseases (CVD) and highlights the potential of epitranscriptomics, specifically RNA modifications, in theranostics. Epitranscriptomics involves studying how modifications of RNA transcripts influence their functions in development, homeostasis, and disease states. The article explores the role of m6A, a prevalent RNA modification, in various cardiovascular conditions and its potential as a biomarker. The use of advanced technologies, such as liquid chromatography and mass spectrometry, allows for precise quantification of RNA modifications and evaluation of their biomarker potential. The article also discusses the potential of RNA therapeutics, including RNA interference and antisense oligonucleotides, in influencing m6A RNA modification. The manipulation of m6A machinery has shown promise in conferring beneficial cardiovascular effects, and the advent of CRISPR technology offers the potential for precise and sequence-specific RNA modifications. The discovery of blood-based epitranscriptomic biosignatures could enhance disease prediction and facilitate personalized theranostic approaches. The article emphasizes the importance of continued research in the RNA field and the potential for collaboration in advancing theranostics options. [Extracted from the article]

Copyright of European Heart Journal is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)